Posts Tagged ‘dog’


In SCIENCE & STEM CELLS, STEM CELLS IN THE NEWS on November 22, 2012 at 8:47 am


Scientists have reversed paralysis in dogs after injecting them with cells grown from the lining of their nose.  The pets had all suffered spinal injuries which prevented them from using their back legs. The Cambridge University team is cautiously optimistic the technique could eventually have a role in the treatment of human patients.  The study is the first to test the transplant in “real-life” injuries rather than laboratory animals.

The only part of the body where nerve fibres continue to grow in adults is the olfactory system.  Found in the at the back of the nasal cavity, olfactory ensheathing cells (OEC) surround the receptor neurons that both enable us to smell and convey these signals to the brain.  The nerve cells need constant replacement which is promoted by the OECs.

For decades scientists have thought OECs might be useful in spinal cord repair. Initial trials using OECs in humans have suggested the procedure is safe.  In the study, funded by the Medical Research Council and published in Brain, the dogs had olfactory ensheathing cells from the lining of their nose removed.  These were grown and expanded for several weeks in the laboratory.

Of 34 pet dogs on the proof of concept trial, 23 had the cells transplanted into the injury site – the rest were injected with a neutral fluid.  Many of the dogs that received the transplant showed considerable improvement and were able to walk on a treadmill with the support of a harness.  None of the control group regained use of its back legs.  The research was a collaboration between the MRC’s Regenerative Medicine Centre and Cambridge University’s Veterinary School.  Professor Robin Franklin, a regeneration biologist at the Wellcome Trust-MRC Stem Cell Institute and report co-author, said: ‘Our findings are extremely exciting because they show for the first time that transplanting these types of cell into a severely damaged spinal cord can bring about significant improvement.  “We’re confident that the technique might be able to restore at least a small amount of movement in human patients with spinal cord injuries but that’s a long way from saying they might be able to regain all lost function. Prof. Franklin said, “the procedure might be used alongside drug treatments to promote nerve fibre regeneration and bioengineering to substitute damaged neural networks.”

The researchers say the transplanted cells regenerated nerve fibres across the damaged region of the spinal cord. This enabled the dogs to regain the use of their back legs and coordinate movement with their front limbs.  The new nerve connections did not occur over the long distances required to connect the brain to the spinal cord. The MRC scientists say in humans this would be vital for spinal injury patients who had lost sexual function and bowel and bladder control.

Prof Geoffrey Raisman, chair of Neural Regeneration at University College London, who discovered olfactory ensheathing cells in 1985 said: “This is not a cure for spinal cord injury in humans – that could still be a long way off. But this is the most encouraging advance for some years and is a significant step on the road towards it.”

He said the clinical benefits were still limited: “This procedure has enabled an injured dog to step with its hind legs, but the much harder range of higher functions lost in spinal cord injury – hand function, bladder function, temperature regulation, for example – are yet more complicated and still a long way away.”

Jasper, a 10-year-old dachshund, is one of the dogs which took part in the trial.

His owner May Hay told me: “Before the treatment we used to have to wheel Jasper round on a trolley because his back legs were useless. Now he whizzes around the house and garden and is able to keep up with the other dogs. It’s wonderful.”


BBC News – Nose cell transplant enables paralysed dogs to walk.

Search and Rescue Dog in 9/11 Attacks Receives Stem Cell Treatment in Burke – Lorton, VA Patch

In STEM CELLS IN THE NEWS on March 20, 2012 at 3:12 am

Search and Rescue Dog in 9/11 Attacks Receives Stem Cell Treatment in Burke

Treatment should help alleviate aches and pains for “Red,” a 12-year-old black Labrador retriever.

 March 19, 2012



A decade ago, “Red,” a black Labrador search and rescue dog, was deployed in the 9/11 attacks at the Pentagon in Arlington.

Many of the hundreds of search and rescue dogs sent to the Pentagon, World Trade Center in New York City and Shanksville, Pa., have since passed away.

On Monday, Red, who is now 12 years old, received a breakthrough stem cell regenerative treatment from Dr. John Herrity, D.V.M., at the Burke Animal Clinic to help ease crippling arthritis and live out her days in greater comfort.

Red was sent to the Pentagon on Sept. 16, 2001, with her owner and handler, Heather Roche of Annapolis, Md. They worked at the site for 11 days, finding remains of victims in the Pentagon’s north parking-lot area. Red later helped in the aftermath of Hurricanes Katrina and Rita.

No longer able to handle tasks like climbing a two-story ladder, Red retired in July 2011. “She still wants to work, but her body just can’t do it anymore,” Roche said.

“This dog gave a lot to us,” Herrity said Monday afternoon after performing the treatment on Red. “They do searches for remains in burned out buildings. It’s the least we can do for these guys.”

Procedure Lets Old Dogs Run, Play Again

The two-part procedure takes a little over an hour and normally costs $2,000 to $2,400. Two other 9/11 dogs that recently received the same stem cell therapy are able to run, climb and play again. The treatment mainly helps larger breed dogs ages 9 and older with hip and arthritis problems.

Herrity has experience with more than two-dozen stem cell operations. MediVet-America, which developed the in-clinic stem cell technology, donated the cost of the procedure and cryogenic banking of additional stem cells.

Veterinarians and researchers describe stem cell regenerative therapy as a major scientific development in the treatment of arthritis, hip dysplasia, ligament and cartilage injuries and other degenerative joint diseases in dogs, cats, horses and other animals. The technology uses an adult animals’ own stem cells to heal itself.

MediVet-America’s treatment involves removing fat tissue from the animal, separating the stem cells from the fat, activating and injecting the cells into the affected areas. Within four to six weeks, animals who were in severe pain with a restricted range of motion are able to walk, run and even jump again. Key to the procedure is an advanced, patented L.E.D. technology that activates millions of dormant stem cells present in fat tissue.

MediVet donated the test kit system for Red’s procedure on Monday.

Two other Sept. 11 search and rescue dogs also have been treated with stem cell therapy and are doing well, according to MediVet. Bailey, a 15 year-old black Lab, underwent the procedure in November. Hoke, a 14 year-old yellow Lab, was treated in December. Both are doing well, according to their handlers, and have resumed normal activity in retirement.

“We are proud to help the unsung canine heroes of 9/11 more than a decade after the attacks,” said MediVet-America CEO Jeremy Delk. “They deserve the very best stem cell therapeutic care that is now being received by animals across the nation.”

Herrity said the recovery process takes about two to three months. “Our society today wants everything done yesterday,” he said. “But that’s not how the body works.”


Search and Rescue Dog in 9/11 Attacks Receives Stem Cell Treatment in Burke – Lorton, VA Patch.


In ALL ARTICLES on October 27, 2011 at 8:57 pm

Tolerance to Composite Tissue Allografts is Dependent on the Administration of Hematopoietic Stem Cells but not Long-Term Engraftment

David Mathes1,2, Jeff Chang1,2, Scott Graves2, Billana Huang2, Tiffany Miwongtum2, Rainer Storb2

1Department of Surgery, Division of Plastic and Reconstructive Surgery, University of Washington; 2Transplantation Biology Research Center, Fred Hutchinson Cancer Research Center; Seattle, Washington, USA

Introduction: Composite tissue allografts (CTA) are a clinical reality.  However, the survival of these transplants is dependent on immunosuppression. This experiment sought to develop a large animal model for the simultaneous transplantation of hematopoietic stem cells (HSC) and CTA using our mixed chimerism protocol and to examine the role of the HSC infusion.

Methods: 4 transplants were performed across a DLA matched, minor mismatch barrier. All dogs received 200 cGy of radiation and a CTA transplant with injection of HSC. 3 dogs underwent the protocol except without an HSC infusion. All dogs received 35 days of post-grafting immunosuppression and were followed for donor cell chimerism and underwent biopsies. Tolerant animals underwent a donor and third-party skin graft. Finally, they were followed for levels of FoxP3 and GranzymeB in the transplanted muscle and skin.

Results: All of the experimental animals demonstrated long-term tolerance to the CTA (497, 467, 465, and 400 days). 3 of 4 dogs had long-term detectable donor chimerism. One dog lost its chimerism at 10 weeks post-transplant but remained tolerant to the CTA. The expression of CD3+ FoxP3 was stable in the tolerant transplanted muscle and skin.  It was also noted to be elevated in the draining lymph node. The three dogs transplanted without an HSC infusion rejected their transplants at 45 days after the cessation of post-grafting immunosuppression. All of the tolerant dogs accepted the donor skin graft and promptly rejected the third-party graft.

Conclusion: The simultaneous transplant of HSC and CTA leads to tolerance. This tolerance induction appears to be dependent on the administration of HSC but not its long-term engraftment. This finding suggests that modifications to the protocol that promote initial engraftment but not long-term presence of donor cells will be key to the development of a protocol that can used on complete mismatched transplants.



In VICTORIES & SUCCESS STORIES on October 27, 2011 at 8:01 pm

SILENCE OF THE LAMBS MEETS STEM CELLS and future transplant recipients win big!!

https://repairstemcell.files.wordpress.com/2011/10/anthony_hopkins_hannibal_lecter.jpg?w=147Remember in Silence of the Lambs, at the end of the movie, when Hannibal Lecter cuts off the guards face and then wears it out to escape?  It turns out, if he had some stem cells to go with that face transplant, he could have just kept on wearing it. 

Surgical researchers did exactly that on four dogs and all 4 of the dogs tolerated the face transplants for over one year without immunosuppressive drugs after the first month.  – David


Surgeons Develop Simultaneous Tissue and Stem Cell Transplant Technique

Released: 10/18/2011 11:00 AM EDT
Embargo expired: 10/27/2011 2:15 PM EDT
Source: American College of Surgeons (ACS)

New method shows promise in eliminating the need for long-term antirejection drugs, particularly for hand and face transplants

Newswise — SAN FRANCISCO: Surgical researchers at the University of Washington, Seattle, have pioneered a method using stem cells that may one day eliminate the need for antirejection drugs in transplants. Primary investigator David Mathes, MD, FACS, and his research fellow Jeff Chang, MD, MS, presented their findings today at the 2011 Clinical Congress of the American College Surgeons. Two groups of patients who might one day benefit from this early research breakthrough are hand and face transplant recipients. To date, survival of these transplants has depended on administering high-dose drugs to patients that suppress the immune system like those used in major organ transplants. However, these drugs are expensive and have a multitude of side effects, the researchers explained.

The surgeons performed simultaneous transplants of vascularized composite allografts—transplanted tissue with the blood vessels intact—and stem cells in four dogs followed by a short course of immune-suppressing drugs. All four dogs accepted the grafts without complications. After about a month, the researchers discontinued all immune system suppressing drugs. One dog rejected its stem cell transplant 10 weeks after the operation, but continued to tolerate the composite allograft for over one year without immunosuppression.

The other three dogs tolerated both stem cells and composite allografts for over one year. The investigators also performed vascularized composite allograft transplants without the stem cells on three other dogs. All three rejected the transplants after immune-suppressing drugs were stopped.

“If this technique works and proceeds into a clinical model, we would be able to transplant patients with either face or hands or even solid organs without the need for long-term immunosuppression drugs,” according to Dr. Chang. Physicians prescribe these drugs to people who have undergone hand and face transplants because organ transplant recipients, such as those receiving a liver or kidney, must take high-dose drugs to suppress the immune system and stave off organ rejection. Innovators of the hand and face transplants have followed this protocol to similarly prevent tissue rejection.

However, the side effects of these drugs have been widely reported. Kidney transplant recipients, for example, have a heightened risk of developing diabetes and hypertension. These drugs also raise the likelihood of infections and malignancy in all transplant recipients, Dr. Chang explained. Moveover, the American Society of Transplant Surgeons has estimated that immune-suppressing drugs can cost up to $25,000 a year per person.

While solid organ transplants are considered life-prolonging procedures in which the benefits outweigh the drug side effects, Dr. Chang noted that hand and face transplants do not fit this category. “Face and hand transplants are not life-saving procedures, so not subjecting these patients to the risks of immunosuppression would certainly be beneficial to them,” Dr. Chang said.

Although this research is still in an early phase, an important new finding the University of Washington study unveiled is the role that stem cells play in making the body tolerant of transplanted tissue, Dr. Chang said. “It’s interesting that you can modulate the immune system in such a way that you can transplant other cells into the recipient and the recipient becomes tolerant of them,” he said.

The study involved vascularized composite allograft transplants matched to the recipient’s tissue type. The next step is to attempt transplants in what Dr. Chang called a “mismatched” setting—where the donor and recipient tissue types do not necessarily match. “If we can get this to work in a mismatched setting it would be more clinically relevant,” Dr. Chang said.

Dr. Mathes and his collaborators at the Fred Hutchinson Cancer Research Center are attempting to develop this experimental model into a more clinical model for humans. The use of a canine model for this research is significant because large animals more closely resemble human anatomy and physiology with regard to composite allograft transplants, whereas “trying this method in small animals, such as laboratory mice, would be more difficult to translate into humans,” Dr. Chang explained.

Although the researchers embarked on developing this technique with hand and face transplants in mind, simultaneous mismatched tissue and stem cell transplantation may also hold promise for solid organ transplants. “If we extend this technique into solid organ transplantation, it would assist with a major problem; whether or not you need a complete match,” Dr. Chang said. “The other problem is supply and demand. If we can break the immunological barriers in such a way that would let us transplant a mismatched kidney, it would help greatly with the shortage of organs.”

David Mathes, MD, FACS, is the primary investigator for this project. Jeff Chang, MD, MS, is his research fellow. Both collaborated with Rainer Storb, MD, at the Fred Hutchinson Cancer Research Center in Seattle.

Surgeons Develop Simultaneous Tissue and Stem Cell Transplant Technique.

For those of you interested in the https://i2.wp.com/www.imodownload.com/imageupload/hcb_01.jpgbehind this, go here:


Stem cell therapy goes to the dogs

In VICTORIES & SUCCESS STORIES on April 1, 2011 at 12:28 pm

Stem cell therapy goes to the dogs

A surgical team at Veterinary Specialty Center in Buffalo Grove removes fat from Doodle, a 9-year-old German Shepherd suffering from osteoarthritis and hip dysplasia. Stem cells will be derived from the fat and injected into the dog./Photo submitted by Veterinary Specialty Center

A surgical team at Veterinary Specialty Center in Buffalo Grove removes fat from Doodle, a 9-year-old German Shepherd suffering from osteoarthritis and hip dysplasia. Stem cells will be derived from the fat and injected into the dog. Photo submitted by Veterinary Specialty Center

Doodle was the first dog to receive the new one-day stem cell procedure in Illinois./Photo submitted by Veterinary Specialty Center

Things were getting bad for Doodle. Despite her youthful name, the 9-year-old German Shepherd was experiencing joint pain from bilateral hip dysplasia and osteoarthritis. She would get sore and tired from long weekend walks and started falling up the stairs.

Her owners, the Dahl family of Oak Brook, had tried different options before landing on animal stem cell regenerative therapy, a procedure that’s a hot topic in the veterinary world. Last week, Doodle received reportedly the first such one-day operation in Illinois at the Veterinary Specialty Center in Buffalo Grove.

The practice of using stem cells, derived from the animal’s fat, to treat joint problems could be discouraging for pet owners because of cost and timing. The animal used to have to go twice to a vet hospital: once for surgery to remove fat cells and once again for the injection of the stem cells into the inflamed joint.  The cost was around $2,700.

Leslie Dahl, Doodle’s owner and a veterinarian herself, didn’t want to go that route. She had tried anti-inflammatory medication, but Doodle’s stomach couldn’t handle it. She tried collagen injections, but they didn’t fully relieve Doodle of her pain. Plus, the animal already was difficult at the vet’s and she was concerned that Doodle would get too anxious between the visits.

So when the Veterinary Specialty Center started looking into a new procedure that allows the stem cells to be processed in the same facility on the same day for about $1,900, Dahl was intrigued.

The process is essentially the same. Fat is removed and then processed by being put in a centrifuge and spun until the stoma stem cells are separated. They are then isolated, activated and injected back into the animal.

In the clinic before a lab was established, the cells were shipped to California, said Mitch Robbins, a surgeon at the Veterinary Specialty Center. The pet would be under anesthesia for removal of the cells, then a second time for the re-injection.

Doodle’s operation, and that of another dog called Fergus, were the center’s firsts in which the stem cells were processed in house, Robbins said.

He said he’s seen about 70 to 80 percent of the animals improve significantly with the treatment that’ s been available since about 2005.

“It’s been around for a little while,” said Kimberly May, a veterinarian and assistant director of professional and public affairs for the Schaumburg-based American Veterinary Medical Association. “We’ve actually been using it in horses for quite a while; now it’s being promoted for joint disease and hip dysphasia. It’s definitely growing, especially for pet owners who are hearing all these anecdotal stories.”

Research is progressing on the treatment’s effectiveness, May said.

“You find out what it really works for and where it doesn’t work,” she said. “We’re still in that stage with the stem cell procedures.”

Robbins said success depends on the animal’s ailments. Pets that don’t respond may be experiencing pain from a source other than  inflammation of the tissues around the joint.

“Some dogs do better, some do worse, some don’t respond at all,” he said.

On average, the animals he treats get re-injected every 18 months, he said. The cells can be stored, with subsequent procedures costing about $600.

Robbins believes the one-day procedure and lower cost will encourage more pet owners to help out their older dogs with arthritis or inflammatory problems. Dahl said her family would have had to euthanize Doodle if pain prevented her from moving, but that would have been a really tough decision since they embrace the dog’s quirky personality.

So far, Doodle’s recovery has been going well. It takes about 10 days to heal from the initial surgery and about four to five weeks to see results.

Doodle is still throwing balls to herself and performing stuffed animal tricks, but is not quite back to going up and down stairs.

“I don’t expect this is going to be a magic bullet to give her back her youth,” Dahl said. “But to get her where she’s not falling and she’s not in pain after going for just a moderate walk, that’s quality of life.

Stem cell therapy goes to the dogs — Buffalo Grove news, photos and events — TribLocal.com.

Stem Cell Technology Treating Many Degenerative Diseases…In Pets

In ALL ARTICLES on March 31, 2011 at 10:14 am

Technology is giving us many new inventions daily. One such recent invention of world class manufacturing technology has been made by Medivet Pty Ltd. The Research and Development Division of the company has introduced a new procedure with the help of which, the veterinarians can extract, process and activate an animal’s own adult stem cells by injecting them back again into the animal’s own body.

Medivet has recently introduced this unique procedure. Several countries worldwide and many international veterinarians today are using this procedure to treat many degenerative diseases such as primary and secondary arthritis, hip dysplasia, damaged or torn ligaments and tendons, joint pain, worn or damaged cartilage etc.

Medivet has spent many years and millions of dollars to introduce this one of the most exciting and valuable treatments ever released, exclusively for the veterinary field. The company is really making big with its American division, Medivet America LLC that is leading the field in sales and Adipose Stem Cell procedures.

Trials are still being conducted at many universities, in Australia and internationally. Also, thousands of Adipose Stem Cell Kits have been supplied to veterinarians enabling them to perform Stem cell procedures including the 14 international countries to which, Medivet is currently exporting the kits.

Stem Cell Technology Treating Many Degenerative Diseases Today | TopNews United States.

New hope for old friends

In ALL ARTICLES, VICTORIES & SUCCESS STORIES on February 25, 2011 at 8:11 pm

Your cherished pet is feeling the effects of old age ... it is  suffering and may need to be put down. Enter stem-cell therapy.

A Tauranga company is offering veterinary clinics a process for stem-cell treatment that improves healing and brightens – even lengthens – the lives of dogs, cats and horses.

The groundbreaking treatment is being applied to osteoarthritis, and ligament and tendon injuries affecting racehorses.

Stemvet New Zealand, established in September 2009, is committed to providing veterinarians with the knowledge and products to make stem-cell therapy an everyday treatment.

It also wants to put New Zealand veterinarians at the forefront of developments in regenerative medicine.

“The treatment certainly relieves pain and slows the ageing process,” said Stemvet co-owner Gil Sinclair.

“The degree of improvement varies with each patient. But in most cases there’s dramatic improvement in the animal’s mobility and wellbeing.”

Dr Sinclair, a veterinarian who has four in-vitro fertilisation (IVF) laboratories in New Zealand and Australia, has been involved with animal reproduction for nearly 30 years. He has recently worked with researchers in Sydney on the development of stem-cell extraction technology and its application in veterinary clinics.

His enthusiastic business partner, Kerry Hitchcock, talks about a dog suffering from osteoarthritis that was “a doormat at home”.

The dog had an intravenous dose of stem cells and its condition improved. In a short time it was bouncing around.

Mr Hitchcock said an inquisitive neighbour asked the dog’s owner what had happened to the dog. “The neighbour was amazed in the change to the dog,” said Mr Hitchcock.

Early cases treated so far have been dogs – between 8 and 14 years – severely affected with osteoarthritis, and young racehorses that have suffered tendon injuries or have osteoarthritis.

Fat tissue containing dormant adult stem cells is taken from the rump of horses and from under the skin of dogs, and from other animals behind their ribs.

Each gram of fat can contain anything from 4.5 million to 28 million stem cells. The fat is digested in a water bath at 37C, then spun in a centrifuge, and the stem cells filtered out.

A platelet concentrate – containing natural stem-cell activators – is extracted from a blood sample. The platelet and other solutions are mixed with the “fat-extracted” stem-cell concentrate to activate the stem cells.

The mixture is then exposed to a photobiostimulator which provides extra activation. The whole process takes three and a half hours.

The now active adult stem cells are reintroduced to the same animal, mostly by direct injection into the affected joints or tissues. Some are administered intravenously and find their way through the blood system to the inflamed area.

“We are talking about adult stem cells that can be guided into promoting health,” said Dr Sinclair. “There is a huge concentration of them in the body but they are non-functional. By taking fat out of the animals and extracting the stem cells and activating them we can improve the healing process.”

Stemvet has become the exclusive New Zealand distributor for Australian-based MediVet stem-cell therapy products and equipment, which includes the water bath, centrifuge, photobiostimulator and extraction kit.

The package, including equipment and kit, costs $15,000 and in the past month six veterinary clinics, in Christchurch, Blenheim, Wellington, Tauranga, Hamilton and Auckland, have signed up. Stemvet provides training, free of charge. Pet owners are charged about $2500 for the treatment – cheaper than the $4000 quoted by an overseas competitor.

Palos Hills Veterinarian Tries New Treatment For Her Dog

In VICTORIES & SUCCESS STORIES on February 17, 2011 at 8:09 pm

A Palos Hills vet leaned on a colleague for an innovative treatment for her own dog.

By Cristel Mohrman

Credit Cristel Mohrman
As a veterinarian, Leslie Dahl knows the obstacles that aging pets can face. And as a pet owner, she has watched her own dog battle the stairs with arthritic hips.  But if all goes as planned, her dog will soon be walking pain-free. Doodle, a German shepherd, became a guinea pig, so to speak, as the first animal in Illinois to undergo a one-day, in-clinic stem cell procedure.

Dr. Mitch Robbins conducted the procedure on Friday at Buffalo Grove’s Veterinary Specialty Center, where he removed fat tissue from Doodle’s abdominal area and used the center’s newest technology to inject the dog’s hip joints with her own stem cells.

“The reason that it works is that those cells that we’re removing and processing and stimulating are cells that are normally associated with the healing process and the inflammatory process in the body,” Robbins said. “So they go into the joint, they reduce some of the inflammation in the joint, they improve and reduce pain, they improve range of motion, they improve use of the joint.”

While the Buffalo Grove clinic has performed about 40 such regenerative therapy procedures over the past four years, until now the extracted materials were shipped off-site for preparation, resulting in a more drawn out and expensive process.

Last week, Veterinary Specialty Center adopted new technology from Kentucky-based MediVet-America, which allows medical professionals to complete the entire process in-house over the course of just a few hours.

Katherine Wilkie, MediVet-America’s lab services director, guided Buffalo Grove’s team through the process, which involves using machinery to separate stem cells from the rest of the animal’s tissue and cleaning it so that it can be re-injected.

While professionals received instruction, Doodle, still groggy from the tissue extraction, waited in a nearby cage. By the end of the day, she was picked up by Dahl, who brought her back to their Oak Park home.

Over the next few weeks, she is expected to regain her mobility, which has been hindered by bilateral hip dysplasia and osteoarthritis.

“With the stem cells, we’re hoping that they buy her some quality relief and improve her quality of life,” said Dahl, who is a veterinarian at Southwest Animal Care Center in Palos Hills. “I want her to be able to play and the next day not have any of the post-exercise inflammation that she’s having now.”

Robbins emphasized that stem cell treatment will not cure arthritis,but in most cases the procedure eases his four-legged patients’ discomfort. He said the treatment has benefited about 75 percent of his patients, and two-thirds have no longer needed pain medication.

That is especially important to pet owners like Dahl, whose German shepherd’s sensitive stomach won’t tolerate more traditional treatments. Last spring, she brought Doodle to Veterinary Specialty Center for collagen gel injections that noticeably improved the dog’s condition. When Doodle’s discomfort returned in recent months and Dahl learned that the treatment was no longer available, she jumped at the chance to test out the stem cell process.

“We’re going to do what we can to make sure she’s with us as long as possible,” Dahl said.

Robbins said stem cell therapy is generally effective for about 18 months. Extra cells are collected during the initial extraction and stored for subsequent injections, he said.

“They are never going to cure the arthritis, but they should do a very good job of controlling the pain that Doodle has, allowing her to resume a better, more normal quality of life,” he said.

MediVet-America’s technology was introduced in the U.S. May 2010, and it is now being used in 23 states, Wilkie said, with one or two procedures taking place in the U.S. each day.

Doctors report success rates ranging from 75 percent to 90 percent, Wilkie said.

The procedure costs about $1,800; nearly $1,000 less than the expense of a multiple-day procedure, which involves the costs of sending the tissue to outside labs.

Robbins said he expects to use the new technology to benefit 20 to 50 dogs and cats per year.

Top of Form

Will Rover outlive Grandma?


In ALL ARTICLES on January 11, 2011 at 1:59 pm


Since the late 1900’s, animal studies, trials and testing have proven the safety and efficacy of adult stem cell treatments.  Here is a small collection of main stream articles that mirror this history of success.












mountain lionhttps://repairstemcell.wordpress.com/2009/02/27/equine-clinic-is-full-service-care-for-hoofed-friends-thecaliforniancom-the-salinas-californian/









The Cardiomyopathy Association | Dogs with cardiomyopathy in stem cell study

In STEM CELLS IN THE NEWS on July 15, 2010 at 10:09 am

Dogs with cardiomyopathy in stem cell study

Doberman pinschers with dilated cardiomyopathy are to undergo stem cell treatment in America

Doberman pinschers with early stage dilated cardiomyopathy (DCM) are to undergo stem cell treatment to help improve their hearts.

Up to 15 dogs are to be treated at the University of Florida’s Veterinary Medical Centre with $72,000 in support from the Doberman Pinscher Club of America.

The chief of the centre’s cardiology service, Amara Estrada, said “Dobermans have the highest prevalence of dilated cardiomyopathy of any breed of dog and also the most devastating course. So this was the most important and emergent group to focus on.”

It is then hoped the research team can pursue larger-scale clinical trials for Dobermans with DCM.

Research has already suggested that stem-cell transplants can help left ventricular pump function in both animals and humans who have had heart attacks.

All the dogs in the study will be anaesthetised and researchers will inject cells via a catheter into the heart. There will be follow-up checks at one month, six months, 12 months and 18 months.

If the new technique is effective, it may result in less expensive treatment compared to open heart surgery, said Dr Estrada.

Down the road, researchers may expand the studies to include other dog breeds in the hope of achieving beneficial results for all dogs.

The procedure ultimately could be available to veterinary specialists some day, she added.

Cardiomyopathy is common in many breeds of dog.

via The Cardiomyopathy Association | Dogs with cardiomyopathy in stem cell study.

%d bloggers like this: